CJD Tissue/Cell Donor Draft Guidance Is Topic Of Upcoming TSE Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA is requesting data to assess the impact of recommendations to reduce the risk of transmission of CJD and vCJD on the availability of human cells, tissues and cellular and tissue-based products (HCT/P)